Results 251 to 260 of about 92,020 (286)
Some of the next articles are maybe not open access.
Immunomodulatory effects of CD38-targeting antibodies
Immunology Letters, 2018The fist in class CD38-targeting antibody, daratumumab, is currently approved as single agent and in combination with standards of care for the treatment of relapsed and refractory multiple myeloma. Based on the high activity and favorable toxicity profile of daratumumab, other CD38 antibodies, such as isatuximab, MOR202, and TAK-079, are being ...
openaire +3 more sources
2014
???????? ???????????????????????? ??? ???????????????????? ???????? ???????????????? ???????????????????????? ??????- ?????????????????????? ?????????????? (??????) ?? ?????????????????????? ???? ???????????????????????? rs6449182 ???????? CD38. ?????????????????????? 249 ?????????????? ?????? ?? 238 ?????? ?????????????????????? ????????????, ?????????
openaire +1 more source
???????? ???????????????????????? ??? ???????????????????? ???????? ???????????????? ???????????????????????? ??????- ?????????????????????? ?????????????? (??????) ?? ?????????????????????? ???? ???????????????????????? rs6449182 ???????? CD38. ?????????????????????? 249 ?????????????? ?????? ?? 238 ?????? ?????????????????????? ????????????, ?????????
openaire +1 more source
CD38 in the age of COVID-19: a medical perspective
Physiological Reviews, 2021Alberto Horenstein +2 more
exaly
CD38 in Hematopoietic Malignancies
2000M, Konopleva, I, Rissling, M, Andreeff
openaire +2 more sources
Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus
New England Journal of Medicine, 2020Lennard Ostendorf +2 more
exaly